Medical Weight Management
A medically supervised GLP-1 program managed by Yuleisy Coto, MSN, APRN, FNP-C. Starts with a full metabolic workup. Medication is titrated with regular monitoring. Weight reduction directly improves musculoskeletal outcomes for patients managing joint degeneration.
Medical weight management at Cobblestone Spine and Joint Institute is a medically supervised program managed by Yuleisy Coto (FL APRN License No. APRN11009024). The program uses GLP-1 receptor agonist therapy as the pharmacological foundation, combined with a full panel blood analysis that establishes the metabolic baseline before any medication begins. Weight is a metabolic problem in most cases of significant obesity. Managing it requires a medical approach, not willpower.
GLP-1 receptor agonists work by mimicking the incretin hormone glucagon-like peptide-1, which the gut releases after eating. They slow gastric emptying, reduce appetite at the hypothalamic level, increase insulin sensitivity, and in higher doses produce direct effects on fat metabolism and cardiovascular risk markers. The clinical literature on semaglutide and tirzepatide is the most robust weight loss evidence base in pharmacological history. Mean weight loss in the SURMOUNT-1 trial with tirzepatide reached 22.5 percent of body weight at 72 weeks among participants without diabetes. These are not modest effects. They are clinically transformative for patients who have not been able to achieve meaningful weight loss through diet and exercise alone.
The Musculoskeletal Case for Weight Management
Every pound of body weight generates approximately four pounds of compressive force across the knee joint per step. A patient who is 40 pounds above their optimal weight is loading each knee with an additional 160 pounds of force with every stride. That load accelerates knee cartilage degeneration. It is one of the primary mechanical drivers of knee osteoarthritis, and no amount of injection therapy or chiropractic work sustains its benefit if the patient continues to carry that load. The same principle applies to hip pain, low back pain, and sacroiliac joint dysfunction, where excess body weight increases the compressive and shear forces on already compromised structures.
Visceral adiposity also produces systemic low-grade inflammation through the release of pro-inflammatory adipokines. That inflammation circulates through joint tissue and is one of the reasons obese patients have higher baseline pain levels and poorer outcomes from both conservative and regenerative treatment. Reducing visceral fat is not just a cosmetic goal. It changes the inflammatory environment in which every othis treatment operates.
Who Is a Good Candidate for Weight Management?
What the Program Includes
The program is built around GLP-1 receptor agonist therapy using semaglutide or tirzepatide, depending on the patient's clinical profile and the evaluation findings. Tirzepatide acts on both the GLP-1 and GIP receptors, producing greater average weight reduction than semaglutide in head-to-head trial comparisons. The SURMOUNT-1 trial reported a mean body weight reduction of 22.5 percent at 72 weeks with tirzepatide in patients without type 2 diabetes. These are meaningful reductions that produce measurable changes in joint loading and inflammatory markers.
Before any medication is prescribed, Yuleisy Coto completes a full metabolic workup including comprehensive blood analysis covering fasting glucose, HOMA-IR, full thyroid panel, sex hormones, inflammatory markers, and lipids. The medication choice and dosing schedule are based on that evaluation. Patients with concurrent hormonal imbalances are also assessed for hormone replacement therapy needs, since low testosterone and hypothyroidism both impair the response to weight loss intervention.
22.5 percent
Mean body weight reduction
At 72 weeks with tirzepatide
The SURMOUNT-1 trial
Monitoring and Adjustment
Follow-up appointments are built into the program at defined intervals. Dosing is escalated gradually using the manufacturer-recommended titration schedule to minimize gastrointestinal side effects. Weight, body composition, and metabolic markers are tracked throughout. For patients also receiving PRP therapy or stem cell therapy for joint conditions, the weight management program runs concurrently, since reducing mechanical load during the regenerative healing window improves long-term outcomes.